Onco’Zine - The International Cancer Network - is raising awareness of the impact of cancer on patients and society. A community for healthcare professionals and their patients. Onco'Zine is Published by Sunvalley Communication in collaboration with the InPress Media Group. Onco'Zine is updated daily.
January 26, 2012 to January 28, 2012 – The Arizona Biltmore
0 Comments 0 LikesFebruary 1, 2012 to February 2, 2012 – Washington Marriott Hotel
0 Comments 0 LikesFebruary 1, 2012 to February 4, 2012 – Vilamoura, Algarve, Portugal
0 Comments 0 Likes1 member
1 member
2 members
1 member
Started by Dr Kamal E.H.MOHAMED Sep 25, 2011. 0 Replies 0 Likes
Posted by Peter Hofland, PhD on January 27, 2012 at 11:00am 0 Comments 0 Likes
Earlier today, the U.S. Food and Drug Administration (FDA) announced that the agency has approved axitinib (Inlyta®, Pfizer Inc) to treat patients with advanced or metastatic renal cell carcinoma (mRCC) who have not responded to another drug for this type of cancer. Axitinib helps keep the cancer from progressing.…
Posted by Peter Hofland, PhD on January 26, 2012 at 11:30am 0 Comments 1 Like
Oral HPV infection is more common among men than women, explaining why men are more prone than women to develop an HPV related head and neck cancer, according to a study presented at the Multidisciplinary Head and Neck Cancer Symposium, held from January 26-28, 2012 in the Biltmore, Phoenix, Arizona.
Human papillomavirus, or HPV, has recently been linked to some types of head and neck cancer that are becoming more prominent in the United States, mostly…
Posted by Peter Hofland, PhD on January 26, 2012 at 11:30am 0 Comments 1 Like
Posted by Peter Hofland, PhD on January 26, 2012 at 11:00am 0 Comments 0 Likes
Head and neck cancers respond well to the anti-cancer drug erlotinib (Tarceva®, Genentech) when it is administered before surgery and a stronger dose is given to patients who smoke, according to a study presented at the Multidisciplinary Head and Neck Cancer Symposium, held from January 26-28, 2012 in the Biltmore, Phoenix, Arizona.
Erlotinib is an oral anti-cancer drug that can slow a…
Posted by Peter Hofland, PhD on January 24, 2012 at 4:00pm 0 Comments 0 Likes
Results from a Phase II clinical trial with IMA910 in patients with advanced colorectal cell carcinoma (CRC), which were presented at the Gastrointestinal Cancers Symposium of the 2012 American Society of Clinical Oncology (ASCO) in San Francisco showed positive results.
IMA910, developed by German clinical-stage biopharmaceutical company immatics biotechnologies GmbH, is therapeutic cancer vaccine…
Posted by Peter Hofland, PhD on January 18, 2012 at 9:30am 0 Comments 0 Likes
The latest data on the investigational drug regorafenib (BAY 73-4506)from the Phase III CORRECT trial(Colorectal cancer treated with regorafenib or placebo after failure of standard therapy) were presented at the 2012 Gastrointestinal Cancers Symposium of the American Society of Clinical Oncology (ASCO-GI), in San Francisco, CA.
Regorafenib (BAY 73-4506) is an an investigational oral multi-kinase inhibitor developed by Bayer which targets angiogenic,…
Posted by Pam Brammann, R.N. on January 12, 2012 at 3:30pm 1 Comment 1 Like
Is there a cancer drug shortage? If you've listened to the news lately, you've probably heard that there is indeed a drug shortage. Hospitals and pharmacies across the United States, Canada, Europe and Australia are running short of important drugs used to treat several forms of cancer and serious infections after a manufacturer decide to temporarily halt production. They are now bracing for possible…
ContinuePosted by Peter Hofland, PhD on January 11, 2012 at 5:30pm 0 Comments 0 Likes
Researchers at the Translational Genomics Research Institute (TGen) and its collaborators have identified a rare, inherited mutation linked to a significantly higher risk of prostate cancer.
A study led by Johns Hopkins University School of Medicine and the University of Michigan…
Posted by Peter Hofland, PhD on January 10, 2012 at 9:00pm 0 Comments 0 Likes
Researchers at Johns Hopkins have shown that DNA changes in a gene that drives the growth of a form of lung cancer can make the cancer’s cells resistant to cancer drugs. The findings show that some classes of drugs won’t work, and certain types of so-called kinase inhibitors like erlotinib—may be…
ContinuePosted by Peter Hofland, PhD on January 10, 2012 at 6:00pm 0 Comments 0 Likes
The investigational drug ganetespib (STA-9090, Synta Pharmaceuticals), a synthetic second-generation Hsp90 inhibitor, slowed the growth of cancer cells taken from non-small cell lung cancer tumors with a mutation in the KRAS gene. The drug was even more active when combined with traditional lung cancer treatments and other investigational targeted therapies, according to preclinical study data.…
To estimate the efficacy and toxicity of AMG 386, an investigational peptide-Fc fusion protein that neutralizes the interaction between the Tie2 receptor and angiopoietin-1/2, plus weekly paclitaxel in patients with recurrent ovarian cancer.
Patients and MethodsPatients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer were randomly assigned 1:1:1 to receive paclitaxel (80 mg/m2 once weekly [QW], 3 weeks on/1 week off) plus intravenous AMG 386 10 mg/kg QW (arm A), AMG 386 3 mg/kg QW (arm B), or placebo QW (arm C). The primary end point was progression-free survival (PFS). Secondary end points included overall survival, objective response, CA-125 response, safety, and pharmacokinetics.
ResultsOne hundred sixty-one patients were randomly assigned. Median PFS was 7.2 months (95% CI, 5.3 to 8.1 months) in arm A, 5.7 months (95% CI, 4.6 to 8.0 months) in arm B, and 4.6 months (95% CI, 1.9 to 6.7 months) in arm C. The hazard ratio for arms A and B combined versus arm C was 0.76 (95% CI, 0.52 to 1.12; P = .165). Further analyses suggested an exploratory dose-response effect for PFS across arms (Tarone's test, P = .037). Objective response rates for arms A, B, and C were 37%, 19%, and 27%, respectively. The incidence of grade ≥ 3 adverse events (AEs) in arms A, B, and C was 65%, 55%, and 64%, respectively. Frequent AEs included hypertension (8%, 6%, and 5% in arms A, B, and C, respectively), peripheral edema (71%, 51%, and 22% in arms A, B, and C, respectively), and hypokalemia (21%, 15%, and 5% in arms A, B, and C, respectively). AMG 386 exhibited linear pharmacokinetic properties at the tested doses.
ConclusionAMG 386 combined with weekly paclitaxel was tolerable, with a manageable and distinct toxicity profile. The data suggest evidence of antitumor activity and a dose-response effect, warranting further studies in ovarian cancer.
To study distribution of coronary artery stenosis among patients with breast cancer (BC) and to assess correlation between radiotherapy (RT) and location of stenosis.
Patients and MethodsA Swedish BC cohort diagnosed from 1970 to 2003 was linked to registers of coronary angiography from 1990 to 2004, which yielded 199 patients. Stenoses of the coronary arteries were graded from 0 to 5, where 0 indicated a normal vessel and 5 indicated occlusion. Two hotspot areas for radiation were defined: proximal right coronary artery (prox RCA), mid and distal left anterior descending artery and distal diagonal (mdLAD + dD). RT regimens were categorized as high or low risk of irradiating the hotspot areas. Left breast/chest wall was considered high risk for mdLAD + dD; left internal mammary chain (IMC), high risk for prox RCA and mdLAD + dD from 1970 to 1995 and thereafter solely for mdLAD + dD; and right IMC, high risk for prox RCA. Other RT targets and no RT were considered low risk. Results were expressed in odds ratios (ORs) and 95% CIs.
ResultsFor irradiated left- versus right-sided BC, the OR for grade 3 to 5 stenosis in mdLAD + dD was 4.38 (95% CI, 1.64 to 11.7), and for grade 4 to 5 stenosis, the OR was 7.22 (95% CI, 1.64 to 31.8). For high-risk RT versus low-risk or no RT, the OR for grade 3 to 5 stenosis in hotspot areas was 1.90 (95% CI, 1.11 to 3.24).
ConclusionAn increase of stenosis in mdLAD + dD in irradiated left-sided BC and an association between high-risk RT and stenosis in hotspot areas for radiation indicate a direct link between radiation and location of coronary stenoses.
Section 3 Emerging Treatment Options
For CME-certification information and other resources, visit www.IMERonline.com/CRPCvide...
Target Audience
Medical oncologists, urologists, radiation oncologi...
Author: imeronline
Added: 01/25/2012
Section 2 mCRPC Progression
For CME-certification information and other resources, visit www.IMERonline.com/CRPCvide...
Target Audience
Medical oncologists, urologists, radiation oncologists, and ...
Author: imeronline
Added: 01/25/2012
Section 1: Identification and Initial Treatment of CRPC Test
For CME-certification information and other resources, visit www.IMERonline.com/CRPCvide...
Target Audience
Medical oncologists, urolog...
Author: imeronline
Added: 01/25/2012
Vital Options International presents Advocacy in Action, bringing together the influential leaders of the cancer advocacy community to address core issues that impact metastatic breast cancer patients...
Author: vitaloptions
Added: 01/23/2012
Vital Options International presents Advocacy in Action, bringing together the influential leaders of the cancer advocacy community to address core issues that impact metastatic breast cancer patients...
Author: vitaloptions
Added: 01/23/2012
© 2012 Created by Peter Hofland, PhD.

